Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

For the record

CMAJ August 12, 2008 179 (4) 316; DOI: https://doi.org/10.1503/cmaj.080998
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Sexually transmitted diseases on the rise

Alberta announced the launch of a $2 million campaign to combat the rise of sexually transmitted diseases on June 17, 2008, a day after releasing figures indicating skyrocketing rates of gonorrhea and chlamydia among young people in the province. The ads will encourage condom use and regular testing for the diseases.

In 2007, there were 112 cases of gonorrhea per 100 000 Alberta males between the ages of 15 and 19, compared to 53 per 100 000 in 2002. For females in the same age group, gonorrhea rates increased from 130 to 208 per 100 000. Reported incidents of chlamydia for males increased by about 25%, while rates among females remained constant.

“There's been a rise in unsafe-sex practices since the AIDS era because our prevention measures have fallen off,” says Dr. Ameeta Singh, an infectious diseases consultant with Alberta Health and Wellness. Surging rates of sexually transmitted diseases have been of national concern since the late 1990s. In 2007, according to Statistics Canada, the national rate per 100 000 of population for chlamydia was 219.5 (compared to 113.9 in 1997), for gonorrhea 34.9 (compared to 14.9), and for syphilis 3.5 (compared to 0.4).

Other countries have reported similar increases. In the United Kingdom, cases of syphilis among people aged 45 to 64 increased 139% between 2002 and 2006, and cases of chlamydia rose 51%. The US Centers for Disease Control and Prevention reported in March 2008 that 1 in 4 teenage girls in the United States has a sexually transmitted disease, which experts claim is due, in part, to the growing popularity of oral sex. An estimated 3.2 million teenage girls in that country are at risk for health problems such as infertility and cervical cancer because they have chlamydia, trichomoniasis, herpes simplex virus or human papillomavirus. — Roger Collier, CMAJ

G8 attention to neglected diseases research welcomed

The Drugs for Neglected Diseases Initiative faces the challenge of running clinical trials on promising drugs in remote parts of the world, where health care infrastructure is minimal, access is difficult and political instability the norm.

So a pledge from Group of 8 leaders to support research into treatments for neglected diseases was very welcome, says Jana Armstrong, director of the organization's newly opened North American branch, based in New York City.

The mission of the 5-year-old independent and non-profit pharmaceutical organization is to discover and develop new drugs, and ensure access to treatments for 3 tropical diseases: sleeping sickness, leishmaniasis and Chagas. Contributions from governments account for about half of its funding, with the balance coming from Médecins Sans Frontières and the Bill and Melinda Gates Foundation.

The G8 has in the past voiced support for treatment for neglected diseases, but the emphasis on research is new, says Armstrong, whose organization has also been instrumental in launching 2 new combination drugs for malaria, a result of product development partnerships.

In early July, the Group of Eight leaders accepted a recommendation from its health experts group to “reinvigorate” efforts to control or eliminate neglected diseases with a 3–5 year period of sustained action that encompasses research, diagnostics and treatment, as well as prevention. No dollar figure was attached to this pledge.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Running clinical trials in remote, hard-to-access parts of the world is one of the challenges faced by the Drugs for Neglected Diseases Initiative. This jeep is en route to patients in Katanda, Democratic Republic of the Congo. Image by: Els Torreele/DNDi

Armstrong says she hopes the G8 pledge will lead to increased funding to allow a “longer term and sustainable approach to working on these diseases.” There is now “no mechanism that ensures that any drug or vaccine development for neglected diseases gets continually funded and taken forward.”

The Initiative was created because the market-driven drug development system was not researching treatments for patients in the developing world.

The non-profit plans to have 6 to 8 new treatments available by 2014; it now has 250 agreements in place, about half with academic and public institutions, and half with pharmaceutical and biotechnology companies, Executive Director Dr. Bernard Pécoul told the organization's first-ever stakeholders meeting held in late June in New York City.

But he warned that the organization has secured only US$18 million in funding, and needs another US$314 million to carry on its work.

Funding preclinical work — gaining access to promising research and existing drugs that might be useful, and signing licensing agreements — is a hurdle for the organization, but a key logistical challenge is running clinical trials in affected, mostly rural areas. The organization has become involved in training and monitoring local clinical trial staff and even having to build wards or centres for clinical research. “We didn't expect that we would have to get into construction,” says Armstrong.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 179 (4)
CMAJ
Vol. 179, Issue 4
12 Aug 2008
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
For the record
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
For the record
CMAJ Aug 2008, 179 (4) 316; DOI: 10.1503/cmaj.080998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
For the record
CMAJ Aug 2008, 179 (4) 316; DOI: 10.1503/cmaj.080998
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Sexually transmitted diseases on the rise
    • G8 attention to neglected diseases research welcomed
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Women experts underrepresented in pandemic coverage
  • What’s important to know about the new COVID-19 variants?
  • Feds update immunization advice with Moderna vaccine approval
Show more News

Similar Articles

Collections

  • Topics
    • Sexually transmitted infections
    • Public health

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire